WoodTrust Financial Corp Purchases 87,287 Shares of Pfizer Inc. (NYSE:PFE)

WoodTrust Financial Corp raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 48.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 269,102 shares of the biopharmaceutical company’s stock after buying an additional 87,287 shares during the period. Pfizer comprises approximately 0.8% of WoodTrust Financial Corp’s portfolio, making the stock its 22nd largest position. WoodTrust Financial Corp’s holdings in Pfizer were worth $7,468,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Creekmur Asset Management LLC purchased a new stake in Pfizer during the fourth quarter valued at about $32,000. VisionPoint Advisory Group LLC boosted its position in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners purchased a new stake in Pfizer during the fourth quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new stake in Pfizer during the fourth quarter valued at about $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.54.

Pfizer Stock Performance

Pfizer stock opened at $27.98 on Friday. The stock’s 50 day simple moving average is $27.90 and its two-hundred day simple moving average is $27.68. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market cap of $158.55 billion, a price-to-earnings ratio of -466.26, a PEG ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the business earned $1.23 earnings per share. The business’s revenue was down 19.5% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.